Lanzox

• Each vial of LANZOX contains 100U of Clostridium botulinum toxin type A

• Indicated for the treatment of strabismus, blepharospasm associated with dystonia including benign essential blepharospasm and hemifacial spasms in patients 12 years of age or older.
• Multiple injections over time required for strabismus over 50 prism dioptre, for restrictive strabismus, Duane’s syndrome with lateral rectus weakness and in secondary strabismus caused by excess correction operation.
• To reduce antagonist contracture in chronic paralytic strabismus in conjuction with reparative surgery.
   

Clinical Research :

• Completed clinical study on The Effects of Botulinum Toxin A on Facial Motoneurons in Xi'an (China).
• Completed clinical study on The Long Term Therapeutic Effects of Botulinum Toxin A for the treatment of Strabismus in Beijing (China).
• Completed clinical study on Botulinum Toxin Type A Treatment in Topical Dystonia in Lanzhou (China).